title: Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
abstract: OBJECTIVE
  Hyperfractionated accelerated radiotherapy (HART) has been combined with chemotherapy (CC) for locally advanced head and neck cancer, but no data from randomized trials are available for a comparison with conventionally fractionated radiotherapy (CFRT) and CC.
  
  
  METHODS
  This monoinstitutional retrospective study compares the results of both treatment schedules: 315 patients with locally advanced carcinoma (UICC stage III and IV) of the oral cavity and the orohypopharynx were treated from January 1990 to March 2006 with a radiochemotherapy combination based on mitomycin C and fluorouracil (HART-CC: 203 patients, CFRT-CC: 112 patients, total dose: 70-72 Gy) with curative intent.
  
  
  RESULTS
  Two- and 4-year survival was 60 and 42 (HART-CC) and 59 and 42% (CFRT-CC; p = 0.82, log-rank test), respectively. Using multivariate Cox regression, pretreatment hemoglobin level, N stage, tumor site but not the year of treatment, gender and T stage were significant prognosticators for survival. For locoregional control, only N stage was significant. The prognostic value of these pretreatment factors did not variate with the fractionation schedule used.
  
  
  CONCLUSIONS
  In combination with CC, there was no trend towards an improved efficacy of HART in comparison with CFRT.
authors.affiliation: Department of Radiation Oncology, University Hospital of Essen, Essen, Germany.
authors.forename: Hanna
authors.initials: H
authors.lastname: Welz
authors.forename: Christoph
authors.initials: C
authors.lastname: Pöttgen
authors.forename: Jehad
authors.initials: J
authors.lastname: Abu Jawad
authors.forename: Arne
authors.initials: A
authors.lastname: Wierlemann
authors.forename: Andrea
authors.initials: A
authors.lastname: Wittig
authors.forename: Georg
authors.initials: G
authors.lastname: Stüben
authors.forename: Volker
authors.initials: V
authors.lastname: Budach
authors.forename: Goetz
authors.initials: G
authors.lastname: Lehnerdt
authors.forename: Klaus
authors.initials: K
authors.lastname: Jahnke
authors.forename: Horst
authors.initials: H
authors.lastname: Sack
authors.forename: Martin
authors.initials: M
authors.lastname: Stuschke
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000379:methods; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012044:Regression Analysis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D005472:Fluorouracil